1. Home
  2. APVO
  3. APVO News

Latest Aptevo Therapeutics Inc. (APVO) News on June 8, 2025

APVO

ACCESS Newswire

17 days ago

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

APVO

ACCESS Newswire

24 days ago

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

APVO

ACCESS Newswire

a month ago

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

APVO

ACCESS Newswire

2 months ago

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

APVO

ACCESS Newswire

2 months ago

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

APVO

ACCESS Newswire

2 months ago

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

APVO

ACCESS Newswire

2 months ago

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment
APVO

Benzinga

3 months ago

Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment

APVO

ACCESS Newswire

3 months ago

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

APVO

ACCESS Newswire

3 months ago

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

APVO

ACCESS Newswire

3 months ago

Aptevo to Participate in March Conferences

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
APVO

ACCESS Newswire

4 months ago

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

APVO

ACCESS Newswire

4 months ago

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

APVO

ACCESS Newswire

5 months ago

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

APVO

ACCESSWIRE

6 months ago

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

APVO

ACCESSWIRE

6 months ago

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

APVO

ACCESSWIRE

6 months ago

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

APVO

ACCESSWIRE

6 months ago

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

APVO

ACCESSWIRE

6 months ago

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

APVO

ACCESSWIRE

7 months ago

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

APVO

ACCESSWIRE

7 months ago

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

APVO

ACCESSWIRE

7 months ago

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

APVO

ACCESSWIRE

7 months ago

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

APVO

ACCESSWIRE

7 months ago

Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
APVO

ACCESSWIRE

9 months ago

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
APVO

ACCESSWIRE

9 months ago

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study
APVO

ACCESSWIRE

9 months ago

Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024
APVO

ACCESSWIRE

9 months ago

Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated
APVO

ACCESSWIRE

10 months ago

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
APVO

ACCESSWIRE

10 months ago

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $2.75 Million Offering
APVO

ACCESSWIRE

a year ago

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules
APVO

ACCESSWIRE

a year ago

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Participating in the BIO International Convention
APVO

ACCESSWIRE

a year ago

Aptevo Participating in the BIO International Convention

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
APVO

ACCESSWIRE

a year ago

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update
APVO

ACCESSWIRE

a year ago

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
APVO

ACCESSWIRE

a year ago

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
APVO

ACCESSWIRE

a year ago

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

Aptevo Therapeutics Provides Pipeline Update
APVO

ACCESSWIRE

a year ago

Aptevo Therapeutics Provides Pipeline Update

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
APVO

ACCESSWIRE

a year ago

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
APVO

ACCESSWIRE

a year ago

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
APVO

ACCESSWIRE

a year ago

Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan
APVO

ACCESSWIRE

a year ago

Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan

APVO

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 02/01/2024

APVO

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 01/31/2024

Greenwave Technology Solutions' Scrap App Continues Capturing Market Share
APVO

PR Newswire

a year ago

Greenwave Technology Solutions' Scrap App Continues Capturing Market Share

180 Degree Capital Corp. Nominates Matthew F. McLaughlin for Election to the Board of comScore, Inc.
APVO

GlobeNewswire

a year ago

180 Degree Capital Corp. Nominates Matthew F. McLaughlin for Election to the Board of comScore, Inc.

FAT Brands Foundation Awards Over $250,000 to Local Non-Profits in 2023
APVO

GlobeNewswire

a year ago

FAT Brands Foundation Awards Over $250,000 to Local Non-Profits in 2023

Visionary Education Group Established a MOU with Algoma University
APVO

PR Newswire

a year ago

Visionary Education Group Established a MOU with Algoma University

Toro Corp. Announces the Completion of the Sale of the M/T Wonder Sirius
APVO

GlobeNewswire

a year ago

Toro Corp. Announces the Completion of the Sale of the M/T Wonder Sirius

RF Industries, Ltd. (NASDAQ:RFIL) Q4 2023 Earnings Call Transcript
APVO

Insider Monkey

a year ago

RF Industries, Ltd. (NASDAQ:RFIL) Q4 2023 Earnings Call Transcript

Keen Vision Acquisition Corporation (NASDAQ:KVAC) most popular amongst retail investors who own 45% of the shares, institutions hold 32%
APVO

Simply Wall St.

a year ago

Keen Vision Acquisition Corporation (NASDAQ:KVAC) most popular amongst retail investors who own 45% of the shares, institutions hold 32%

APVO

Thomson Reuters StreetEvents

a year ago

Q4 2023 RF Industries Ltd Earnings Call

RF Industries Reports Fourth Quarter and Fiscal Year 2023 Financial Results
APVO

ACCESSWIRE

a year ago

RF Industries Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Urgently Secures Engagement with Global Top 5 Automotive OEM
APVO

GlobeNewswire

a year ago

Urgently Secures Engagement with Global Top 5 Automotive OEM

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada
APVO

PR Newswire

a year ago

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

Northann Corp. Receives Approval from U.S. Patent and Trademark Office for Core Technology in Benchwick 3D Printing Ecosystem
APVO

GlobeNewswire

a year ago

Northann Corp. Receives Approval from U.S. Patent and Trademark Office for Core Technology in Benchwick 3D Printing Ecosystem

Toro Corp. Announces the Sale of the M/T Wonder Sirius for $33.8 Million with an Expected Net Gain of $20.9 Million
APVO

GlobeNewswire

a year ago

Toro Corp. Announces the Sale of the M/T Wonder Sirius for $33.8 Million with an Expected Net Gain of $20.9 Million

LiveOne (Nasdaq: LVO) Provides Update for Its $10M Stock Repurchase Program
APVO

GlobeNewswire

a year ago

LiveOne (Nasdaq: LVO) Provides Update for Its $10M Stock Repurchase Program

DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) largest shareholders are individual investors with 52% ownership, insiders own 37%
APVO

Simply Wall St.

a year ago

DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) largest shareholders are individual investors with 52% ownership, insiders own 37%

17EdTech Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement
APVO

GlobeNewswire

a year ago

17EdTech Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement

Apollomics Completes Patient Enrollment for Phase 3 Trial of Leukemia Treatment
APVO

Exec Edge

a year ago

Apollomics Completes Patient Enrollment for Phase 3 Trial of Leukemia Treatment

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
APVO

GlobeNewswire

a year ago

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Precipio Announces Christina Valauri joins the Board of Directors
APVO

GlobeNewswire

a year ago

Precipio Announces Christina Valauri joins the Board of Directors

Trust Stamp has partnered with Scurid to deliver highly secure, AI-powered in-field authentication for seamless human-machine interaction
APVO

GlobeNewswire

a year ago

Trust Stamp has partnered with Scurid to deliver highly secure, AI-powered in-field authentication for seamless human-machine interaction

Zhongchao First Half 2023 Earnings: US$0.18 loss per share (vs US$0.004 profit in 1H 2022)
APVO

Simply Wall St.

a year ago

Zhongchao First Half 2023 Earnings: US$0.18 loss per share (vs US$0.004 profit in 1H 2022)

Cenntro Regains Compliance with Nasdaq Minimum Bid Price Rule
APVO

Business Wire

a year ago

Cenntro Regains Compliance with Nasdaq Minimum Bid Price Rule

Insider Buying: CEO Steven Lisi Acquires 77,775 Shares of Beyond Air Inc
APVO

GuruFocus.com

a year ago

Insider Buying: CEO Steven Lisi Acquires 77,775 Shares of Beyond Air Inc

PodcastOne (NASDAQ: PODC) Acquires Exclusive Rights to Hit Podcast Was I In A Cult? From Hosts Liz Iacuzzi and Tyler Measom
APVO

GlobeNewswire

a year ago

PodcastOne (NASDAQ: PODC) Acquires Exclusive Rights to Hit Podcast Was I In A Cult? From Hosts Liz Iacuzzi and Tyler Measom

Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
APVO

GlobeNewswire

a year ago

Addex Shareholders Approve All Resolutions at Extraordinary General Meeting

PRINCIPAL REAL ESTATE INCOME FUND CONTINUES SHARE REPURCHASE PROGRAM
APVO

PR Newswire

a year ago

PRINCIPAL REAL ESTATE INCOME FUND CONTINUES SHARE REPURCHASE PROGRAM

Linkage Global Inc Announces Pricing of $6,000,000 Initial Public Offering
APVO

GlobeNewswire

a year ago

Linkage Global Inc Announces Pricing of $6,000,000 Initial Public Offering

NCS Multistage Holdings, Inc. Settles Outstanding Commercial Litigation with No Cash Payment By Company
APVO

GlobeNewswire

a year ago

NCS Multistage Holdings, Inc. Settles Outstanding Commercial Litigation with No Cash Payment By Company

Presto’s Voice™ AI Solution Projected to Capitalize on Strong Momentum as Company Releases 2024 Projected Annualized Run Rate
APVO

GlobeNewswire

a year ago

Presto’s Voice™ AI Solution Projected to Capitalize on Strong Momentum as Company Releases 2024 Projected Annualized Run Rate

HomeTrust Bancshares (HTBI) Soars 5.4%: Is Further Upside Left in the Stock?
APVO

Zacks

a year ago

HomeTrust Bancshares (HTBI) Soars 5.4%: Is Further Upside Left in the Stock?

APVO

PR Newswire

a year ago

Zhongchao Inc. Collaborates with a Public Health Foundation to Support Sustainable and Effective Cancer Treatments

MicroAlgo Inc. announced plans to establish a practice base to train graduate students for the university
APVO

PR Newswire

2 years ago

MicroAlgo Inc. announced plans to establish a practice base to train graduate students for the university

Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More
APVO

Zacks

2 years ago

Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More

Senstar Technologies Reports Third Quarter 2023 Financial Results
APVO

PR Newswire

2 years ago

Senstar Technologies Reports Third Quarter 2023 Financial Results

Duluth Holdings Inc (DLTH) Reports Q3 2023 Financial Results Amidst Challenging Retail Environment
APVO

GuruFocus.com

2 years ago

Duluth Holdings Inc (DLTH) Reports Q3 2023 Financial Results Amidst Challenging Retail Environment

Investors in HomeTrust Bancshares (NASDAQ:HTBI) have seen returns of 27% over the past three years
APVO

Simply Wall St.

2 years ago

Investors in HomeTrust Bancshares (NASDAQ:HTBI) have seen returns of 27% over the past three years

PAVmed Inc. (NASDAQ:PAVM) Q3 2023 Earnings Call Transcript
APVO

Insider Monkey

2 years ago

PAVmed Inc. (NASDAQ:PAVM) Q3 2023 Earnings Call Transcript

MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering
APVO

Business Wire

2 years ago

MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering

Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference
APVO

GlobeNewswire

2 years ago

Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference

GOLD ROYALTY REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS - CONTINUED GROWTH DRIVEN BY RECENT ACQUISITIONS
APVO

PR Newswire

2 years ago

GOLD ROYALTY REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS - CONTINUED GROWTH DRIVEN BY RECENT ACQUISITIONS

Intellinetics Grows Revenues 10% in Q3 2023; 27% Year-to-Date
APVO

Business Wire

2 years ago

Intellinetics Grows Revenues 10% in Q3 2023; 27% Year-to-Date

Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update
APVO

ACCESSWIRE

2 years ago

Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update

Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics
APVO

GlobeNewswire

2 years ago

Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics

Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates
APVO

Zacks

2 years ago

Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates

LightPath Technologies, Inc. (NASDAQ:LPTH) Q1 2024 Earnings Call Transcript
APVO

Insider Monkey

2 years ago

LightPath Technologies, Inc. (NASDAQ:LPTH) Q1 2024 Earnings Call Transcript

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call Transcript
APVO

Insider Monkey

2 years ago

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call Transcript

APVO

Thomson Reuters StreetEvents

2 years ago

Q1 2024 LightPath Technologies Inc Earnings Call

APVO

Thomson Reuters StreetEvents

2 years ago

Q3 2023 Lineage Cell Therapeutics Inc Earnings Call

APVO

Associated Press Finance

2 years ago

Paramount Gold: Fiscal Q1 Earnings Snapshot

The past year for Veru (NASDAQ:VERU) investors has not been profitable
APVO

Simply Wall St.

2 years ago

The past year for Veru (NASDAQ:VERU) investors has not been profitable

Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
APVO

Business Wire

2 years ago

Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

SWK Holdings Corporation Announces Financial Results for Third Quarter 2023
APVO

PR Newswire

2 years ago

SWK Holdings Corporation Announces Financial Results for Third Quarter 2023

Sotherly Hotels Inc. (SOHO) Reports Mixed Q3 2023 Results Amidst Market Challenges
APVO

GuruFocus.com

2 years ago

Sotherly Hotels Inc. (SOHO) Reports Mixed Q3 2023 Results Amidst Market Challenges

APVO

Associated Press Finance

2 years ago

Sotherly Hotels: Q3 Earnings Snapshot

Sotherly Hotels Inc. Reports Financial Results for the Third Quarter Ended September 30, 2023
APVO

GlobeNewswire

2 years ago

Sotherly Hotels Inc. Reports Financial Results for the Third Quarter Ended September 30, 2023

Verano Holdings Corp. (VRNOF) Reports Q3 Loss, Lags Revenue Estimates
APVO

Zacks

2 years ago

Verano Holdings Corp. (VRNOF) Reports Q3 Loss, Lags Revenue Estimates

Share on Social Networks: